Advertisement
News
Subscribe to MDT Magazine News

BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU

August 17, 2010 9:33 am | by Bio-Medicine.Org | Comments

NOVATO, Calif., Aug. 17 /- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on neuropsychiatric symptoms in subjects with phenylketonuria...

TOPICS:

Advanced Life Sciences to Participate in Key Infectious Disease Conference

August 17, 2010 9:32 am | by Bio-Medicine.Org | Comments

CHICAGO, Aug. 17 /- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS ), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the...

TOPICS:

VirtuOx and Watermark Medical Announce Strategic Alliance to Expand Sleep Apnea Home Sleep Testing Solutions

August 17, 2010 9:32 am | by Bio-Medicine.Org | Comments

CORAL SPRINGS, Fla., Aug. 17 /- VirtuOx, Inc., a medical technology services company and industry leader in delivering home sleep testing solutions, today announced an agreement with Watermark Medical, a privately-held, medical products and services company currently servicing the...

TOPICS:
Advertisement

Gentiva completes $1B Odyssey HealthCare deal

August 17, 2010 8:45 am | by The Associated Press | Comments

Home health services company Gentiva Health Services Inc. said Tuesday its acquisition of hospice care provider Odyssey HealthCare Inc. has closed.The all-cash deal valued Odyssey at $27 per share and cost about $1 billion including fees and expenses, Gentiva said. Gentiva agreed to buy Odyssey...

TrinityCare Senior Living, Inc. Announces Second Quarter Operating Results

August 17, 2010 2:45 am | by The Associated Press | Comments

http://www.trinitycare.com () —TrinityCare Senior Living, Inc. (OTCBB: TCSR) (the "Company"), which develops, manages and owns faith-based senior living facilities, today announced its operating results for the second quarter of 2010.For the six months ended June 30, 2010, the Company reported...

Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer

August 17, 2010 12:33 am | by Bio-Medicine.Org | Comments

DUBLIN and MYSTIC, Conn., Aug. 17 /- Amarin Corporation plc (Nasdaq: AMRN ), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that Colin W. Stewart has been appointed President, Chief Executive Officer (CEO) and a member of the Company's...

TOPICS:

Oridion to Present Results to New Study for the Integrated Pulmonary Index(TM) at ATACCC Conference

August 17, 2010 12:32 am | by Bio-Medicine.Org | Comments

Oridion to Present Results to New Study for the Integrated Pulmonary... -- JERUSALEM and NEEDHAM, Massachusetts, August 17, 2010 /-

TOPICS:

Delcath launches stock offering

August 16, 2010 5:45 pm | by The Associated Press | Comments

Medical device maker Delcath Systems Inc. said Monday it has started an offering of about 5.2 million shares to raise funds to pay for clinical trials, research and development and other costs.The offering is expected to close Aug. 20.Delcath has granted the underwriter a 30-day option to buy...

Advertisement

IMS Health names Bousbib as new CEO

August 16, 2010 1:45 pm | by The Associated Press | Comments

Health-care market intelligence provider IMS Health Inc. on Monday said United Technologies Corp. executive Ari Bousbib will become its chief executive officer on Sept. 1.Bousbib, 48, was most recently president of United Technology's commercial companies, which include Otis Elevator Co. and...

FDA Proposes Withdrawal of Low Blood Pressure Drug

August 16, 2010 1:35 pm | by Bio-Medicine.Org | Comments

SILVER SPRING, Md., Aug. 16 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today proposed to withdraw approval of the drug midodrine hydrochloride, used to treat the low blood pressure condition orthostatic hypotension, because required post-approval studies that verify...

TOPICS:

Midodrine hydrochloride: FDA Proposes Withdrawal of Low Blood Pressure Drug

August 16, 2010 1:31 pm | by U.S. Food & Drug Administration | Comments

Companies failed to provide evidence of clinical benefit of midodrine hydrochloride because required post-approval studies that verify the clinical benefit of the drug have not been done.

TOPICS:

Endologix Enters Development Agreement and Exclusive License for Balloon Expandable Stent Technology

August 16, 2010 10:34 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., Aug. 16 /- Endologix, Inc. (Nasdaq: ELGX ), developer of minimally invasive treatments for aortic disorders, announced today that it has entered into a development agreement and exclusive license with Evasc Medical Systems Corp., for its balloon expandable stent...

TOPICS:

Springer adds Neurotherapeutics to journals portfolio

August 16, 2010 10:33 am | by EurekAlert | Comments

(Springer) Beginning in 2011, Springer will publish Neurotherapeutics, the official Journal of the American Society for Experimental NeuroTherapeutics. With the switch to Springer, Neurotherapeutics will change its format of publishing review articles only to offering original research...

TOPICS:

PRA International Hosts Audio Conference on CV Drug Development

August 16, 2010 10:33 am | by Bio-Medicine.Org | Comments

RALEIGH, N.C., Aug. 16 /- PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific...

TOPICS:

NSF Awards $3M Stem Cell Bio-Manufacturing Program to Georgia Tech

August 16, 2010 10:33 am | by Georgia Tech Institute of Technology | Comments

The NSF has awarded $3 million to Georgia Tech to fund a unique research program on stem cell bio-manufacturing. The effort is focused on developing engineering methods for stem cell production to meet the anticipated demand for stem cells.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading